BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT). The Company is the parent company and general partner of BioMed Realty, L.P. The Company owns, acquires, develops, redevelops, leases and manages laboratory and office space for the life science industry. The Company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are located in markets, which has centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York, New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (the United Kingdom) and research parks located near or adjacent to universities and their related medical systems. The Company owns interests in properties comprising approximately 17.5 million rentable square feet.
Industry, Sector and Symbol:
- Sector: Financials
- Industry: Commercial REITs
- Sub-Industry: Office REITs
- Symbol: NYSE:BMR
- CUSIP: 09063H10
- Web: www.biomedrealty.com/
- Market Cap: $4.81 billion
- Outstanding Shares: 202,210,000
- 50 Day Moving Avg: $24.00
- 200 Day Moving Avg: $22.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 15.77
- P/E Growth: 0
- Net Margins: 18.98%
- Return on Equity: 3.73%
- Return on Assets: 2.07%
Frequently Asked Questions for Biomed Realty Trust (NYSE:BMR)
What is Biomed Realty Trust's stock symbol?
Biomed Realty Trust trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMR."
How were Biomed Realty Trust's earnings last quarter?
Biomed Realty Trust Inc (NYSE:BMR) issued its quarterly earnings results on Tuesday, April, 28th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.37 by $0.04. The firm had revenue of $178.01 million for the quarter, compared to analysts' expectations of $167.08 million. Biomed Realty Trust had a return on equity of 3.73% and a net margin of 18.98%. The firm's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 EPS. View Biomed Realty Trust's Earnings History.
Who are some of Biomed Realty Trust's key competitors?
Some companies that are related to Biomed Realty Trust include Federal Realty Investment Trust (FRT), VEREIT (VER), Land Securities Group plc (LAND), Kilroy Realty Corporation (KRC), Douglas Emmett (DEI), Liberty Property Trust (LPT), British Land Company PLC (BLND), EPR Properties (EPR), Dupont Fabros Technology (DFT), SEGRO plc (SGRO), STORE Capital Corporation (STOR), Hammerson plc (HMSO), Cousins Properties Incorporated (CUZ), PS Business Parks (PSB), Empire State Realty Trust (ESRT), Intu Properties PLC (INTU), Derwent London Plc (DLN) and Shaftesbury plc (SHB).
Who are Biomed Realty Trust's key executives?
Biomed Realty Trust's management team includes the folowing people:
- Greg N. Lubushkin, Chief Financial Officer
- James R. Berens, President of Wexford Science & Technology
- Jonathan Paul Klassen, Executive Vice President, General Counsel, Secretary
- John P. Bonanno, Executive Vice President, Leasing & Development
- Karen A. Sztraicher, Executive Vice President - Asset Management
How do I buy Biomed Realty Trust stock?
Shares of Biomed Realty Trust can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biomed Realty Trust's stock price today?
MarketBeat Community Rating for Biomed Realty Trust (NYSE BMR)MarketBeat's community ratings are surveys of what our community members think about Biomed Realty Trust and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Biomed Realty Trust stock can currently be purchased for approximately $23.81.
Consensus Ratings for Biomed Realty Trust (NYSE:BMR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Biomed Realty Trust (NYSE:BMR)
(Data available from 9/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/22/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
|10/10/2015||Cowen and Company||Downgrade||Outperform -> Market Perform||$24.00||N/A|
|10/9/2015||BMO Capital Markets||Downgrade||Market Perform||N/A|
|10/9/2015||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
|10/9/2015||Robert W. Baird||Downgrade||Outperform -> Neutral||$24.00||N/A|
|9/21/2015||Mizuho||Lower Price Target||Neutral||$23.00 -> $21.00||N/A|
Earnings History for Biomed Realty Trust (NYSE:BMR)Earnings History by Quarter for Biomed Realty Trust (NYSE BMR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/28/2015||Q115||$0.37||$0.41||$167.08 million||$178.01 million||View||Listen|
|8/5/2014||Q214||$0.36||$0.40||$160.80 million||$171.16 million||View||Listen|
|8/7/2013||Q213||$0.39||$0.37||$143.47 million||$159.64 million||View||Listen|
|2/6/2013||Q412||$0.34||$0.36||$134.72 million||$138.80 million||View||Listen|
|11/1/2012||Q312||$0.33||$0.34||$130.32 million||$134.54 million||View||N/A|
Earnings Estimates for Biomed Realty Trust (NYSE:BMR)
Current Year EPS Consensus Estimate: $1.77 EPS
Next Year EPS Consensus Estimate: $1.51 EPS
Current Dividend Information for Biomed Realty Trust (NYSE:BMR)
|Most Recent Dividend:||10/15/2015|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||0.00% (Based on This Year's Estimates)|
0.00% (Based on Next Year's Estimates)
|Track Record:||7 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Biomed Realty Trust (NYSE BMR)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Biomed Realty Trust (NYSE:BMR)Insider Trades by Quarter for Biomed Realty Trust (NYSE:BMR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/17/2015||John P Bonanno||EVP||Sell||4,800||$21.01||$100,848.00|| |
|6/15/2015||James R Berens||Insider||Sell||2,000||$19.99||$39,980.00|| |
|6/15/2015||John P Bonanno||EVP||Sell||5,000||$19.85||$99,250.00|| |
|3/16/2015||Margaret Faye Wilson||Director||Buy||2,300||$21.76||$50,048.00|| |
|9/8/2014||Stephen A Willey||CAO||Sell||1,388||$22.50||$31,230.00|| |
|8/13/2014||Alan D Gold||CEO||Sell||26,615||$22.17||$590,054.55|| |
|8/13/2014||Matthew G Mcdevitt||VP||Sell||16,000||$22.01||$352,160.00|| |
|6/3/2014||Matthew G Mcdevitt||VP||Sell||7,000||$21.91||$153,370.00|| |
|5/14/2014||Alan Gold||CEO||Sell||25,000||$21.18||$529,500.00|| |
|5/12/2014||Stephen Willey||CAO||Sell||4,840||$21.00||$101,640.00|| |
|3/11/2014||Stephen Willey||CAO||Sell||7,931||$20.25||$160,602.75|| |
|2/11/2014||Matthew Mcdevitt||VP||Sell||60,000||$20.28||$1,216,800.00|| |
|11/23/2012||Matthew G Mcdevitt||VP||Sell||5,223||$19.05||$99,498.15|| |
Headline Trends for Biomed Realty Trust (NYSE:BMR)
Latest Headlines for Biomed Realty Trust (NYSE:BMR)
Biomed Realty Trust (BMR) Chart for Wednesday, September, 20, 2017